Literature DB >> 27892610

JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.

Anna Sophie Klaeschen1, Dominik Wolf2, Peter Brossart2, Thomas Bieber1, Joerg Wenzel1.   

Abstract

This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2-kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho-JAK2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epiCS). Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CXCL10; JAK/STAT pathway; chilblain lupus erythematosus; interferon; kinase inhibitor

Mesh：

Substances：

Year:  2017        PMID： 27892610     DOI： 10.1111/exd.13253

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN： 0906-6705            Impact factor:   3.960


  14 in total

Review 1.  Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.

Authors:  Thomas Bieber
Journal:  Nat Rev Drug Discov       Date:  2021-08-20       Impact factor: 84.694

Review 2.  [Biologicals and small molecules for systemic lupus erythematosus].

Authors:  M Aringer; N Leuchten; T Dörner
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

Review 3.  The influence of interferon on healthy and diseased skin.

Authors:  Grace A Hile; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Cytokine       Date:  2018-12-06       Impact factor: 3.861

Review 4.  Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update.

Authors:  Yashaar Chaichian; Vibeke Strand
Journal:  Clin Rheumatol       Date:  2021-01-07       Impact factor: 2.980

Review 5.  Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.

Authors:  Colton J Garelli; Maggi Ahmed Refat; Padma P Nanaware; Zaida G Ramirez-Ortiz; Mehdi Rashighi; Jillian M Richmond
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

Review 6.  Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.

Authors:  Alessia Alunno; Ivan Padjen; Antonis Fanouriakis; Dimitrios T Boumpas
Journal:  Cells       Date:  2019-08-15       Impact factor: 6.600

7.  Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs.

Authors:  Guillermo Ruiz-Irastorza; George Bertsias
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

8.  Shared inflammatory and skin-specific gene signatures reveal common drivers of discoid lupus erythematosus in canines, humans and mice.

Authors:  Colton J Garelli; Neil B Wong; Cesar Piedra-Mora; Linda M Wrijil; Gina Scarglia; Clement N David; Ramón M Almela; Nicholas A Robinson; Jillian M Richmond
Journal:  Curr Res Immunol       Date:  2021-03-31

Review 9.  The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases.

Authors:  Jessica L Turnier; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2020-12-01       Impact factor: 5.422

10.  Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.

Authors:  Tanja Fetter; Paul Smith; Tugce Guel; Christine Braegelmann; Thomas Bieber; Joerg Wenzel
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.